Also listed on Alnylam Pharmaceuticals, Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Nov 10, 2029 · Low confidence
20-year base term ends Nov 10, 2029
Grace period ended Nov 6, 2026 · no payment on record as of the Nov 17, 2026 fee file · lapse expected
Nov 10, 2009
Nov 10, 2029
Nov 6, 2018
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 2 maintenance fees is paid so far. Confidence: Low: the grace period for its second maintenance fee ended Nov 6, 2026 with no payment on record. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 10, 2009, when application PCT/US2009/063931, the earliest non-provisional in its chain, was filed (this one was filed May 23, 2017) | Nov 10, 2029 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 9,682,139) | resolves to Nov 10, 2029, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | Read from the payments on the fee record: none for this window, and its grace period has ended. No fee event states a lapse, and USPTO's status still reads "Patented Case". | grace period ended Nov 6, 2026 | Low confidence |
| Computed term end | The steps above, in order | Nov 10, 2029 | Low confidence |
This family
| Application PCT/US2009/063931 | PCT application no patent term | no patent term |
| US 8,999,351 | In force Nov 2030 | Nov 2030 |
| US 9,682,139 | Lapsed on the fee record Jun 2025 | Jun 2025 |
| US 10,117,941 | this patent Nov 2029 | Nov 2029 |
| US 10,821,186 | In force Nov 2029 | Nov 2029 |
| Application 17/065,208 | Abandoned not computed | not computed |
| Application 18/110,791 | Abandoned not computed | not computed |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Aug 10, 2017 Reel 43262, frame 674 | Manoharan, Muthiah; Rajeev, Kallanthottathil G.; Jayaraman, Muthusamy; Nair, Jayaprakash K.; Maier, Martin; Butler, David; Eltepu, Laxman | Alnylam Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Aug 10, 2017 Reel 43262, frame 728 | Alnylam Pharmaceuticals, Inc. | Tekmira Pharmaceuticals Corporation | Assignment of Assignor's Interest |
| Aug 10, 2017 Reel 43262, frame 788 | Tekmira Pharmaceuticals Corporation | Arbutus Biopharma Corporation | Change of Name |
| Jul 27, 2018 Reel 46640, frame 764 | Protiva Biotherapeutics Inc.; Arbutus Biopharma Corporation | Arbutus Biopharma Corporation | Merger and Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer resolved from the filed document, referencing US 9,682,139, ends no earlier than this term, so it caps nothing.